Oncotelic Therapeutics Opens Up Enrollment For STOP-PC Clinical Trial Amid Rise In Pancreatic Cancer Cases

In a groundbreaking development, Oncotelic Therapeutics (OTCQB: OTLC) has opened up enrollment for its STOP-PC clinical trial amid a notable rise in pancreatic cancer cases in recent years. Early-onset pancreatic cancer has seen a nearly 15% increase from 2010-2019, alarming healthcare professionals globally.

With a mere 12% five-year survival rate, pancreatic cancer is anticipated to become the second leading cause of cancer-related deaths in the U.S. by 2030. It is projected that 64,440 Americans will receive a pancreatic cancer diagnosis in 2024. The global market for pancreatic cancer was valued at $2.22 billion in 2022 and is projected to reach approximately $7.91 billion by 2032, emphasizing the dire need for more therapeutic options.

Oncotelic Therapeutics aims to address this need through its lead immuno-oncology drug candidate, OT-101. The drug has shown promise in treating deadly cancers like pancreatic cancer by inhibiting a protein called Transforming Growth Factor Beta (TGF-β), which is known to suppress the immune system, help cancer cells evade the immune system, and increase the growth and spread of cancer cells.

Phase 2 studies of OT-101 have demonstrated promising results in treating pancreatic cancer, melanoma, and glioblastoma, with strong efficacy and safety outcomes among treated patients. Recognizing the urgent unmet needs in pancreatic cancer treatment, Oncotelic Therapeutics is now seeking participants for its upcoming STOP-PC clinical trial.

The trial aims to evaluate the effectiveness of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer. Previous data has shown that OT-101 has significant activity as a standalone treatment, with reported overall survival rates surpassing existing drug outcomes.

This phase 2/3 trial will assign participants to receive OT-101 plus mFOLFIRINOX or mFOLFIRINOX alone as second-line therapy after their cancer has progressed. Dr. Vuong Trieu, CEO of Oncotelic, expressed optimism about the trial, stating that the company believes the trial will deliver a decisive win against pancreatic cancer.

For those interested in participating in the STOP-PC clinical trial, more information can be found by clicking here. Additionally, there is an explainer video available here. The efforts of Oncotelic Therapeutics in conducting this trial serve as a beacon of hope for those affected by pancreatic cancer, offering a potential breakthrough in the treatment of this aggressive and challenging disease.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Opens Up Enrollment For STOP-PC Clinical Trial Amid Rise In Pancreatic Cancer Cases.